Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx Ocular UK
AAV5-hRKp.RPGR is an adeno-associated virus serotype 5 gene therapy carrying the human RPGR gene, delivered by sub-retinal injection. It is being studied in X-linked retinitis pigmentosa, an inherited retinal disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04671433 | Phase 3 | X-Linked Retinitis Pigmentosa | Completed | MGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
X-Linked Retinitis Pigmentosa
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.
See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGTX catalysts and pipeline →